Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1182687

	registered interest
	date	04/03/2020
	answering body	Department for International Trade
	answering dept id	202
	answering dept short name	International Trade
	answering dept sort name	International Trade
	hansard heading	Trade Agreements: USA
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Trade, whether she plans to negotiate a carve-out provision based on the definition by the European Public Services Union excluding (a) the NHS and (b) other public services from a trade deal with the US.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	25147
	answer	answer is ministerial correction date of answer 09/03/2020 answer text <p>The UK’s public services, including the NHS, are protected by specific carve-outs, exceptions and reservations in the trade agreements to which the UK is a party, and the UK will continue to ensure that the same rigorous protections are included in future trade agreements. Decisions about public services will continue to be made by the UK Government (or the Devolved Administrations, where appropriate), not by our trade partners.</p><p> </p><p>The Government has been clear that the NHS is not, and never will be, for sale to the private sector, whether overseas or domestic and this position was reaffirmed in our negotiating objectives for a UK-US Free Trade Agreement published on 2 March 2020.</p><p> </p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 09/03/2020 12:17:14 answering member 1526 label Biography information for Greg Hands
	tabling member	4432 label Biography information for Patrick Grady

1182688

	registered interest
	date	04/03/2020
	answering body	Department for International Trade
	answering dept id	202
	answering dept short name	International Trade
	answering dept sort name	International Trade
	hansard heading	Trade Agreements: USA
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Trade, what assessment she has made of the potential merits of protecting regulatory data exclusivity for innovative drugs in a UK-US trade deal.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	25148
	answer	answer is ministerial correction date of answer 09/03/2020 answer text <p>The Government’s objectives for US negotiations state that we will secure provisions that protect the UK’s world-leading intellectual property standards and seek an effective and balanced regime which supports innovation within the pharmaceutical sector, while reflecting wider public interests such as ensuring patient access to medicines.</p><p>The Government is clear that when negotiating free trade agreements, the NHS and the price the NHS pays for medicines will not be on the table. We will not agree to measures which undermine the Government’s ability to deliver our NHS manifesto commitments.</p><p> </p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 09/03/2020 12:07:38 answering member 1526 label Biography information for Greg Hands
	tabling member	4432 label Biography information for Patrick Grady

1182689

	registered interest
	date	04/03/2020
	answering body	Department for International Trade
	answering dept id	202
	answering dept short name	International Trade
	answering dept sort name	International Trade
	hansard heading	Trade Agreements: USA
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Trade, what steps the Government is taking to protect the role of the National Institute for Health and Care Excellence in regulating drug prices in the event of a UK-US trade deal.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	25149
	answer	answer is ministerial correction date of answer 09/03/2020 answer text <p>The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department for Health and Social Care. Questions about NICE should be referred to my Rt Hon Friend the Secretary of State for Health &amp; Social Care.</p><p> </p><p>The Government has been clear that the price the NHS pays for drugs is not on the table in trade negotiations. This position was reaffirmed in our negotiating objectives for a UK-US Free Trade Agreement published on 2 March 2020.</p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 09/03/2020 12:12:59 answering member 1526 label Biography information for Greg Hands
	tabling member	4432 label Biography information for Patrick Grady

1546432

	registered interest
	date	29/11/2022
	answering body	Department for International Trade
	answering dept id	202
	answering dept short name	International Trade
	answering dept sort name	International Trade
	hansard heading	Trade Agreements: India
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Trade, what assessment she has made of the potential merits of making the terms of any draft UK-India free-trade deal subject to a vote by the House of Commons.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	98810
	answer	answer is ministerial correction date of answer 08/12/2022 answer text <p>The Government is committed to ensuring that Parliament can effectively scrutinise the UK’s trade deals. It is the Government’s view that to give Parliament binding votes over international agreements would fundamentally change the UK’s constitutional settlement and undermine the Government’s flexibility to negotiate deals that best serve the interests of UK businesses, consumers and communities.</p><p> </p><p>The India trade agreement will be subject to pre-ratification scrutiny through the Constitutional Reform and Governance Act. Furthermore, any legislative changes required to give effect to the agreement will also be scrutinised and passed by Parliament in the usual way.</p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 08/12/2022 14:42:45 answering member 1526 label Biography information for Greg Hands previous answer version 39318 answering member constituency Chelsea and Fulham answering member printed Greg Hands answering member 1526 label Biography information for Greg Hands
	tabling member	4432 label Biography information for Patrick Grady

1280000

	registered interest
	date	25/01/2021
	answering body	Department for International Trade
	answering dept id	202
	answering dept short name	International Trade
	answering dept sort name	International Trade
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Trade, what discussions she has had with the World Trade Organisation on the development of intellectual property waiver agreements to facilitate the mass production of coronavirus vaccines.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	142978
	answer	answer is ministerial correction date of answer 28/01/2021 answer text <p>The UK has engaged regularly in debates at the World Trade Organisation’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council and other international institutions to promote affordable and equitable global access to COVID-19 vaccines, including in developing countries. As part of this, the UK has encouraged evidence-based discussions between WTO members to find real solutions to the issues at hand within the multilateral intellectual property framework.</p><p> </p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 28/01/2021 11:42:22 answering member 1526 label Biography information for Greg Hands
	tabling member	4432 label Biography information for Patrick Grady